Would be surprised if India doesn't allow export of Hydroxychloroquine to US: Trump

Image
Press Trust of India Washington
Last Updated : Apr 07 2020 | 7:24 AM IST

US President Donald Trump has said he would be surprised if India did not allow the export of Hydroxychloroquine tablets to the United States despite a request made to New Delhi over the subject.

Last week Trump said that he has sought help from Prime Minister Narendra Modi to allow the sale of Hydroxychloroquine tablets ordered by the US to treat the growing number of coronavirus patients in his country, hours after India banned the export of the anti-malarial drug.

I would be surprised if he would, you know, because India does very well with the United States, Trump told reporters during a press briefing at the White House on Monday.

Hydroxychloroquine tablet is used to prevent and treat malaria, lupus and rheumatoid arthritis, among other ailments.

The drug is seen as to offer a viable therapeutic solution to coronavirus that has so far taken the lives of more than 10,000 Americans and infected over 3.6 lakhs, just in a matter of weeks.

Last month, India imposed a ban on export on Hydroxychloroquine, on which Trump is now banking heavily in the treatment of COVID-19 patients.

India has received similar requests from several other countries including its immediate neighbours like Sri Lanka and Nepal. India has said that it is reviewing its export ban order.

Notably, India's decision to ban the exports of Hydroxychloroquine is driven by its desire to take stock of the domestic requirements and ensure that the country has enough in its kitty.

Reiterating that for many years, India has been taking advantage of the US on trade, Trump said that he would be surprised if New Delhi was to stop export of Hydroxychloroquine to the US.

So, I would be surprised if that were his decision. He'd have to tell me that. I spoke to him Sunday morning, called him, and I said we'd appreciate your allowing our supply to come out. If he doesn't allow it to come out, that would be okay, but of course there may be retaliation. Why wouldn't there be? Trump said.

On Monday, a senior State Department official said that India has been a significant partner of the US in the pharmaceutical sector and it expects similar cooperation to continue between the economies.

India has long been a significant partner of the United States and the pharmaceutical sector, Alice G Wells, the Acting Assistant Secretary of State for South and Central Asia, told reporters during a press briefing.

The Trump administration has already created a national strategic stockpile of 29 million doses of the malaria drug, anticipating that its test results on more than 1,500 COVID-19 patients in New York is yielding positive results.

Scientists have begun testing Hydroxychloroquine and chloroquine as candidates for potential COVID-19 treatments and the FDA last week issued an Emergency Use Authorization for the prescription of the drugs in certain circumstances.

In addition to New York, COVID-19 patients in several States are being treated with Hydroxychloroquine, including Michigan and Texas.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 07 2020 | 7:24 AM IST

Next Story